Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Kazuo Fujihara et al.|The Lancet|2019Cited by 722
Placebo-controlled study in neuromyelitis optica—Ethical and design considerationsBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|Multiple Sclerosis Journal|2015Cited by 72
Challenges and opportunities in designing clinical trials for neuromyelitis opticaBrian G. Weinshenker, Michael R. Yeaman, Gerard Barron et al.|Neurology|2015Cited by 46